Advice
Following an abbreviated submission
budesonide (Novolizer) inhaler is accepted for use within NHS Scotland for the treatment of persistent asthma in adults and children over 6 years of age.
Budesonide (Novolizer) inhaler offers an alternative to existing dry powder inhaled formulations of budesonide at a similar cost.
Download detailed advice28KB (PDF)
Medicine details
- Medicine name:
- budesonide 200mcg (Novolizer®) inhaler
- SMC ID:
- 306/06
- Indication:
- Asthma
- Pharmaceutical company
- Meda Pharmaceuticals Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 11 September 2006